Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
A Feasibility and Phase II Study of Proton Beam Radiotherapy for Patients With Cervical Cancer and FDG-PET Positive Para-aortic Lymph Nodes
RATIONALE: Specialized radiation therapy, such as proton beam radiotherapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving proton beam radiation therapy together with cisplatin works in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer and positive lymph nodes.
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the feasibility of proton beam radiotherapy in patients with cervical cancer and FDG-positive para-aortic lymph nodes.
SECONDARY OBJECTIVES:
I. To determine the incidence of acute toxicity of concurrent weekly cisplatin chemotherapy in addition to pelvic and para-aortic irradiation using proton radiotherapy with intracavitary brachytherapy in patients with carcinoma of the uterine cervix with pelvic and para-aortic nodal involvement as demonstrated by FDG-PET.
II. To assess late complications from irradiation using proton beam therapy in place of conventional photon beam therapy.
III. To compare the dose distribution to tumor and surrounding normal structures using DVHs (Dose Volume Histograms) generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes.
IV. To evaluate whether there is a benefit to concurrent weekly cisplatin chemotherapy in addition to pelvic and para-aortic proton beam radiotherapy with intracavitary brachytherapy as evidenced by time to local failure, time to distant failure, time to other failures and overall survival in patients with carcinoma of the uterine cervix with pelvic and para-aortic nodal involvement as demonstrated by FDG-PET.
OUTLINE:
Patients undergo CT, MRI, or FDG-PET imaging scans for radiotherapy treatment planning. Patients then undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 2 years and then annually for 3 years.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion
- Patients must have histologically documented carcinoma of the uterine cervix
- FIGO Stage IB to IVA
- Patients must have no distant metastases apart from positive lymph nodes by FDG PET
- Patients must have a Karnofsky Performance Status of >= 60
- Treatment plan includes cisplatin and patient has no medical contraindications to the administration of cisplatin
- Adequate bone marrow function: WBC >= 3000/mm^3; platelets >= 75,000 mm^3
- Adequate renal function: creatinine =< 2.0 mg/dl (urinary diversion is permitted to improve renal function)
- Patients must have bilirubin =< 1.5 mg/dl
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- FDG PET Scan evidence of distant disease
- No prior surgery for treatment of disease other than exploratory laparotomy or biopsy will be allowed
- No previous systemic chemotherapy will be allowed
- No prior pelvic radiation therapy is permitted other than transvaginal irradiation to control bleeding will be allowed
- Women of childbearing potential who have a positive result on screening serum pregnancy test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I
Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks.
Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
|
Given IV
Other Names:
Undergo external proton beam radiation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feasibility
|
|
|
Acute toxicity, as assessed by NCI CTC Version 4.0
Time Frame: Within 60-90 days following completion of proton therapy
|
Within 60-90 days following completion of proton therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Late toxicity, as assessed by RTOG/EORTC late morbidity scoring system
Time Frame: More than 90 days after starting therapy
|
More than 90 days after starting therapy
|
|
Clinical efficacy (time to local failure, time to distant failure, overall survival)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lillie Lin, Abramson Cancer Center of the University of Pennsylvania
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 22808
- NCI-2009-01350
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.